Histopathologic Staging at Initial Diagnosis of Mycosis Fungoides and the Sézary Syndrome
Authors:
- Joyce L. EddyJEJoyce L. Eddy
- Robert W. MakuchRMRobert W. Makuch
- A. B. FischmannAFA. B. Fischmann
- Geraldine P. SchechterGSGeraldine P. Schechter
- Mary MatthewsMMMary Matthews
- Eli GlatsteinEGEli Glatstein
- Daniel C. IhdeDIDaniel C. Ihde
- Frederic KayeFKFrederic Kaye
- Stephen R. VeachSVStephen R. Veach
- Ruby PhelpsRPRuby Phelps
- Terry O'COnnorTOTerry O'COnnor
- 1 September 1988
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 109 (5) , 372-382
Abstract
To determine the optimal staging evaluation at the time of initial diagnosis of mycosis fungoides or the Sézary syndrome. Retrospective review of a uniformly staged inception cohort. Single-institution tertiary care center. 152 consecutive patients who had mycosis fungoides with or without the Sézary syndrome within 6 months of the initial definitive diagnosis. A detailed staging evaluation including physical examination, routine laboratory studies, chest roentgenogram, lymphangiogram, peripheral blood smear, lymph node biopsy, bone marrow aspirate or biopsy, and liver biopsy in selected patients. Univariate adverse prognostic features at initial diagnosis in patients with mycosis fungoides included (P less than 0.01) one or more cutaneous tumors or generalized erythroderma, adenopathy, blood smear involvement with Sézary cells, lymph node effacement, eosinophilia, and visceral involvement. Important, independent prognostic factors in a multivariate analysis are the presence of visceral disease and type of skin involvement. A staging system based on histopathologic evaluation of skin, lymph nodes, blood, and visceral sites provides more comprehensive prognostic information than clinical evaluation of skin disease and adenopathy. Patients may be divided at initial presentation into three prognostic groups: good-risk patients, who have plaque-only skin disease without lymph node, blood, or visceral involvement (median survival, greater than 12 years); intermediate-risk patients, who have cutaneous tumors, erythroderma, or plaque disease with node or blood involvement but no visceral disease or node effacement (median survival, 5 years); and poor-risk patients, who have visceral involvement or node effacement (median survival, 2.5 years).Keywords
This publication has 45 references indexed in Scilit:
- T-Cell Lymphoproliferative Syndrome Associated with Human T-Cell Leukemia/Lymphoma VirusAnnals of Internal Medicine, 1984
- Clinical Staging for Cutaneous T-Cell LymphomaAnnals of Internal Medicine, 1984
- Septicemic complications of the cutaneous T-cell lymphomasThe American Journal of Medicine, 1981
- Prognostic variables in mycosis fungoidesCancer, 1981
- Phenotypic Characterization of Cutaneous T-Cell LymphomaNew England Journal of Medicine, 1981
- Mycosis fungoides: Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factorCancer, 1980
- Prospective Staging Evaluation of Patients with Cutaneous T-Cell LymphomasAnnals of Internal Medicine, 1980
- Hepatic involvement in the cutaneous T-cell lymphomas. Results of percutaneous biopsy and peritoneoscopyCancer, 1980
- The Sézary syndrome: a malignant proliferation of helper T cells.Journal of Clinical Investigation, 1976
- Cutaneous T-Cell Lymphomas: The Sézary Syndrome, Mycosis Fungoides, and Related DisordersAnnals of Internal Medicine, 1975